CLChristopher T. Lemke

Christopher T. Lemke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher T. Lemke has a total of 134 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models

    by Ulrike Rauh, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, James McFarland, Christopher T. Lemke, Nicolas Werbeck, et al.

    The MCL1 gene is frequently amplified in cancer and codes for the antiapoptotic protein myeloid cell leukemia 1 (MCL1), which confers resistance to the current standard of care. Therefore, MCL1 is an attractive anticancer target. Here we describe BRD-810 as a potent and selective MCL1 inhibitor and its key design principle of rapid systemic clearance to potentially minimize area under the curve-driven toxicities associated with MCL1 inhibition. BRD-810 induced rapid cell killing within 4 h in vitro but, in the same 4-h window, had no impact on cell viability or troponin I release in human induced pluripotent stem cell-derived cardiomyocytes, even at suprapharmacologic concentrations. In vivo BRD-810 induced efficacy in xenograft hematological and solid tumor models despite the short residence time of BRD-810 in plasma. In totality, our data support the hypothesis that short-term inhibition of MCL1 with BRD-810 can induce apoptosis in tumor cells while maintaining an acceptable safety profile. We, therefore, intend to advance BRD-810 to clinical trials.


  • Open Access

    Supplementary Figures S1-S7 from Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers

    by Douglas A. Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, Kevin S. Kapner, Michael H. Rosenthal, Bryanna L. Norden, Haley Barnes, Sara Ehnstrom, Alvin A. Morales-Giron, Lauren K. Brais, et al.

    Supplementary Figure S1 shows IC50 values of KRASG12C inhibitors for KRASG12C, NRASG12C, HRASG12C.Supplementary Figure S2 shows inhibition of NRASG12C by sotorasib in 293T and MOLT-4 cells.Supplementary Figure S3 shows effect of amino acid substitutions in NRASG12C or KRASG12C on signaling in response to sotorasib and adagrasib.Supplementary Figure S4 who's location of isoform-variable residues relative to Switch-II binders.Supplementary Figure S5 shows crystal structures of KRASG12C inhibitors and interactions with His95.Supplementary Figure S6 shows chemical structures of switch-II pocket-binding KRASG12C inhibitors.Supplementary Figure S7 shows structural model of sotorasib interaction with Leu95.

  • Open Access

    Supplementary Figures S1-S7 from Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers

    by Douglas A. Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, Kevin S. Kapner, Michael H. Rosenthal, Bryanna L. Norden, Haley Barnes, Sara Ehnstrom, Alvin A. Morales-Giron, Lauren K. Brais, et al.

    Supplementary Figure S1 shows IC50 values of KRASG12C inhibitors for KRASG12C, NRASG12C, HRASG12C.Supplementary Figure S2 shows inhibition of NRASG12C by sotorasib in 293T and MOLT-4 cells.Supplementary Figure S3 shows effect of amino acid substitutions in NRASG12C or KRASG12C on signaling in response to sotorasib and adagrasib.Supplementary Figure S4 who's location of isoform-variable residues relative to Switch-II binders.Supplementary Figure S5 shows crystal structures of KRASG12C inhibitors and interactions with His95.Supplementary Figure S6 shows chemical structures of switch-II pocket-binding KRASG12C inhibitors.Supplementary Figure S7 shows structural model of sotorasib interaction with Leu95.

  • Open Access

    Data from Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers

    by Douglas A. Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, Kevin S. Kapner, Michael H. Rosenthal, Bryanna L. Norden, Haley Barnes, Sara Ehnstrom, Alvin A. Morales-Giron, Lauren K. Brais, et al.

    KRASG12C inhibitors, like sotorasib and adagrasib, potently and selectively inhibit KRASG12C through a covalent interaction with the mutant cysteine, driving clinical efficacy in KRASG12C tumors. Because amino acid sequences of the three main RAS isoforms—KRAS, NRAS, and HRAS—are highly similar, we hypothesized that some KRASG12C inhibitors might also target NRASG12C and/or HRASG12C, which are less common but critical oncogenic driver mutations in some tumors. Although some inhibitors, like adagrasib, were highly selective for KRASG12C, others also potently inhibited NRASG12C and/or HRASG12C. Notably, sotorasib was five-fold more potent against NRASG12C compared with KRASG12C or HRASG12C. Structural and reciprocal mutagenesis studies suggested that differences in isoform-specific binding are mediated by a single amino acid: Histidine-95 in KRAS (Leucine-95 in NRAS). A patient with NRASG12C colorectal cancer treated with sotorasib and the anti-EGFR antibody panitumumab achieved a marked tumor response, demonstrating that sotorasib can be clinically effective in NRASG12C-mutated tumors.Significance:These studies demonstrate that certain KRASG12C inhibitors effectively target all RASG12C mutations and that sotorasib specifically is a potent NRASG12C inhibitor capable of driving clinical responses. These findings have important implications for the treatment of patients with NRASG12C or HRASG12C cancers and could guide design of NRAS or HRAS inhibitors.See related commentary by Seale and Misale, p. 698.This article is featured in Selected Articles from This Issue, p. 695

  • Open Access

    Data from Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers

    by Douglas A. Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, Kevin S. Kapner, Michael H. Rosenthal, Bryanna L. Norden, Haley Barnes, Sara Ehnstrom, Alvin A. Morales-Giron, Lauren K. Brais, et al.

    KRASG12C inhibitors, like sotorasib and adagrasib, potently and selectively inhibit KRASG12C through a covalent interaction with the mutant cysteine, driving clinical efficacy in KRASG12C tumors. Because amino acid sequences of the three main RAS isoforms—KRAS, NRAS, and HRAS—are highly similar, we hypothesized that some KRASG12C inhibitors might also target NRASG12C and/or HRASG12C, which are less common but critical oncogenic driver mutations in some tumors. Although some inhibitors, like adagrasib, were highly selective for KRASG12C, others also potently inhibited NRASG12C and/or HRASG12C. Notably, sotorasib was five-fold more potent against NRASG12C compared with KRASG12C or HRASG12C. Structural and reciprocal mutagenesis studies suggested that differences in isoform-specific binding are mediated by a single amino acid: Histidine-95 in KRAS (Leucine-95 in NRAS). A patient with NRASG12C colorectal cancer treated with sotorasib and the anti-EGFR antibody panitumumab achieved a marked tumor response, demonstrating that sotorasib can be clinically effective in NRASG12C-mutated tumors.Significance:These studies demonstrate that certain KRASG12C inhibitors effectively target all RASG12C mutations and that sotorasib specifically is a potent NRASG12C inhibitor capable of driving clinical responses. These findings have important implications for the treatment of patients with NRASG12C or HRASG12C cancers and could guide design of NRAS or HRAS inhibitors.See related commentary by Seale and Misale, p. 698.This article is featured in Selected Articles from This Issue, p. 695

  • Open Access

    Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers

    by Douglas A. Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, Kevin S. Kapner, Michael H. Rosenthal, Bryanna L. Norden, Haley Barnes, Sara Ehnstrom, Alvin A. Morales-Giron, Lauren K. Brais, et al.

    KRASG12C inhibitors, like sotorasib and adagrasib, potently and selectively inhibit KRASG12C through a covalent interaction with the mutant cysteine, driving clinical efficacy in KRASG12C tumors. Because amino acid sequences of the three main RAS isoforms—KRAS, NRAS, and HRAS—are highly similar, we hypothesized that some KRASG12C inhibitors might also target NRASG12C and/or HRASG12C, which are less common but critical oncogenic driver mutations in some tumors. Although some inhibitors, like adagrasib, were highly selective for KRASG12C, others also potently inhibited NRASG12C and/or HRASG12C. Notably, sotorasib was five-fold more potent against NRASG12C compared with KRASG12C or HRASG12C. Structural and reciprocal mutagenesis studies suggested that differences in isoform-specific binding are mediated by a single amino acid: Histidine-95 in KRAS (Leucine-95 in NRAS). A patient with NRASG12C colorectal cancer treated with sotorasib and the anti-EGFR antibody panitumumab achieved a marked tumor response, demonstrating that sotorasib can be clinically effective in NRASG12C-mutated tumors. Significance: These studies demonstrate that certain KRASG12C inhibitors effectively target all RASG12C mutations and that sotorasib specifically is a potent NRASG12C inhibitor capable of driving clinical responses. These findings have important implications for the treatment of patients with NRASG12C or HRASG12C cancers and could guide design of NRAS or HRAS inhibitors. See related commentary by Seale and Misale, p. 698. This article is featured in Selected Articles from This Issue, p. 695


  • Open Access

    Identification of highly selective SIK1/2 inhibitors that modulate innate immune activation and suppress intestinal inflammation

    by Holger Babbe, Thomas B. Sundberg, Mark Tichenor, Mark Seierstad, Genesis Bacani, James Berstler, Wenying Chai, Leon Chang, De Michael Chung, Kevin Coe, et al.

    The salt-inducible kinases (SIK) 1–3 are key regulators of pro- versus anti-inflammatory cytokine responses during innate immune activation. The lack of highly SIK-family or SIK isoform-selective inhibitors suitable for repeat, oral dosing has limited the study of the optimal SIK isoform selectivity profile for suppressing inflammation in vivo. To overcome this challenge, we devised a structure-based design strategy for developing potent SIK inhibitors that are highly selective against other kinases by engaging two differentiating features of the SIK catalytic site. This effort resulted in SIK1/2-selective probes that inhibit key intracellular proximal signaling events including reducing phosphorylation of the SIK substrate cAMP response element binding protein (CREB) regulated transcription coactivator 3 (CRTC3) as detected with an internally generated phospho-Ser329-CRTC3-specific antibody. These inhibitors also suppress production of pro-inflammatory cytokines while inducing anti-inflammatory interleukin-10 in activated human and murine myeloid cells and in mice following a lipopolysaccharide challenge. Oral dosing of these compounds ameliorates disease in a murine colitis model. These findings define an approach to generate highly selective SIK1/2 inhibitors and establish that targeting these isoforms may be a useful strategy to suppress pathological inflammation.


  • Open Access

    Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists

    by Douglas L. Orsi, Steven J. Ferrara, Stephan Siegel, Anders Friberg, Léa Bouché, Elisabeth Pook, Philip Lienau, Joseph P. Bluck, Christopher T. Lemke, Gizem Akcay, et al.


  • Open Access

    Multimodal small-molecule screening for human prion protein binders

    by Andrew G. Reidenbach, Michael F. Mesleh, Dominick Casalena, Sonia M. Vallabh, Jayme L. Dahlin, Alison J. Leed, Alix I. Chan, Dmitry L. Usanov, Jenna B. Yehl, Christopher T. Lemke, et al.


  • Enantiomeric Atropisomers Inhibit HCV Polymerase and/or HIV Matrix: Characterizing Hindered Bond Rotations and Target Selectivity

    by Steven R. LaPlante, Pat Forgione, Colette Boucher, René Coulombe, James Gillard, Oliver Hucke, Araz Jakalian, Marc-André Joly, George Kukolj, Christopher Lemke, et al.

    An anthranilic acid series of allosteric thumb pocket 2 HCV NS5B polymerase inhibitors exhibited hindered rotation along a covalent bond axis, and the existence of atropisomer chirality was confirmed by NMR, HPLC analysis on chiral supports, and computational studies. A thorough understanding of the concerted rotational properties and the influence exerted by substituents involved in this steric phenomenon was attained through biophysical studies on a series of truncated analogues. The racemization half-life of a compound within this series was determined to be 69 min, which was consistent with a class 2 atropisomer (intermediate conformational exchange). It was further found by X-ray crystallography that one enantiomer of a compound bound to the intended HCV NS5B polymerase target whereas the mirror image atropisomer was able to bind to an unrelated HIV matrix target. Analogues were then identified that selectively inhibited the former. These studies highlight that atropisomer chirality can lead to distinct entities with specific properties, and the phenomenon of atropisomerism in drug discovery should be evaluated and appropriately managed.